Adverse Events Related to Biologicals Used for Patients With Multiple Sclerosis: A Comparison Between Information Originating From Regulators and From the Scientific Community

European Journal of Neurology - United Kingdom
doi 10.1111/ene.14259
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Wiley

Related search

Deaths From Preventable Adverse Events Originating in Hospitals

BMJ Quality and Safety
MedicineHealth Policy
2017English

Adverse Events With Fatal Outcome Associated With Alemtuzumab Treatment in Multiple Sclerosis

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2019English

Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association

Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular MedicineCardiology
2019English

Mixed Treatment Comparison of Adverse Events for BG-12, Glatiramer, and Teriflunomide for the Treatment of Relapsing Forms of Multiple Sclerosis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Comparison of Antibodies With Amylase Activity From Cerebrospinal Fluid and Serum of Patients With Multiple Sclerosis

PLoS ONE
Multidisciplinary
2016English

Melanoma Complicating Treatment With Natalizumab for Multiple Sclerosis: A Report From the Southern Network on Adverse Reactions (SONAR)

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2017English

Comparison of Antibodies Hydrolyzing Myelin Basic Protein From the Cerebrospinal Fluid and Serum of Patients With Multiple Sclerosis

PLoS ONE
Multidisciplinary
2014English

P3.04-20 Correlation of Immune-Related Adverse Events and Response From Immune Checkpoint Inhibitors in Patients With Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Patients With Epileptic Seizures and Multiple Sclerosis in a Multiple Sclerosis Center in Southern Germany Between 2003–2015

Frontiers in Neurology
Neurology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy